Clinical benefit of imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial
Martin E. Blackstein(Mount Sinai Hospital), George D. Demetri(American Society of Clinical Oncology), Robert S. Benjamin(The University of Texas MD Anderson Cancer Center), Christopher D.�M. Fletcher(Brigham and Women's Hospital), Margaret von Mehren(Temple University Health System), Michael C. Heinrich(VA Portland Health Care System), Jonathan A. Fletcher(Harvard University), Cathryn Rankin(Cleveland Clinic), Ernest C. Borden(Cleveland Clinic), Charles D. Blanke(SWOG Cancer Research Network)
Cited by 17
Related Papers
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k
Interferons at age 50: past, current and future impact on biomedicine
|Nature Reviews Drug Discovery|2007|1.2k